Follow
hazem elkady
hazem elkady
Associate professor of Pharmaceutical Medicinal Chemistry and Drug Design Department
Verified email at azhar.edu.eg
Title
Cited by
Cited by
Year
New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies
H Elkady, A Elwan, HA El-Mahdy, AS Doghish, A Ismail, MS Taghour, ...
Journal of enzyme inhibition and medicinal chemistry 37 (1), 403-416, 2022
1022022
Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents
MA El-Zahabi, H Sakr, K El-Adl, M Zayed, AS Abdelraheem, SI Eissa, ...
Bioorganic chemistry 104, 104218, 2020
802020
Discovery of thieno [2, 3-d] pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents
SA El-Metwally, MM Abou-El-Regal, IH Eissa, ABM Mehany, HA Mahdy, ...
Bioorganic Chemistry 112, 104947, 2021
792021
Design, synthesis, docking, DFT, MD simulation studies of a new nicotinamide-based derivative: In vitro anticancer and VEGFR-2 inhibitory effects
EB Elkaeed, RG Yousef, H Elkady, IMM Gobaara, BA Alsfouk, DZ Husein, ...
Molecules 27 (14), 4606, 2022
742022
New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis
NA Alsaif, MA Dahab, MM Alanazi, AJ Obaidullah, AA Al-Mehizia, ...
Bioorganic Chemistry 110, 104807, 2021
742021
Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: In-vitro anticancer evaluation and in …
MS Taghour, H Elkady, WM Eldehna, NM El-Deeb, AM Kenawy, ...
Journal of Enzyme Inhibition and Medicinal Chemistry 37 (1), 1903-1917, 2022
702022
Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers
MM Alanazi, IH Eissa, NA Alsaif, AJ Obaidullah, WA Alanazi, AF Alasmari, ...
Journal of Enzyme Inhibition and Medicinal Chemistry 36 (1), 1760-1782, 2021
692021
New quinoxaline-based VEGFR-2 inhibitors: Design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies
MM Alanazi, H Elkady, NA Alsaif, AJ Obaidullah, HM Alkahtani, ...
RSC advances 11 (48), 30315-30328, 2021
522021
Design, synthesis, in silico ADMET profile and GABA‐A docking of novel phthalazines as potent anticonvulsants
AGA El‐Helby, RRA Ayyad, MF Zayed, HS Abulkhair, H Elkady, K El‐Adl
Archiv Der Pharmazie 352 (5), 1800387, 2019
492019
Design and synthesis of new 4-(2-nitrophenoxy) benzamide derivatives as potential antiviral agents: Molecular modeling and in vitro antiviral screening
AE Abdallah, MS Alesawy, SI Eissa, EM El-Fakharany, MH Kalaba, ...
New Journal of Chemistry 45 (36), 16557-16571, 2021
482021
Phthalazine-1, 4-dione derivatives as non-competitive AMPA receptor antagonists: design, synthesis, anticonvulsant evaluation, ADMET profile and molecular docking
AGA El-Helby, RRA Ayyad, K El-Adl, H Elkady
Molecular diversity 23, 283-298, 2019
472019
Multi-step in silico discovery of natural drugs against COVID-19 targeting main protease
EB Elkaeed, FS Youssef, IH Eissa, H Elkady, AA Alsfouk, ML Ashour, ...
International Journal of Molecular Sciences 23 (13), 6912, 2022
452022
Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers
NA Alsaif, MS Taghour, MM Alanazi, AJ Obaidullah, AA Al-Mehizia, ...
Journal of enzyme inhibition and medicinal chemistry 36 (1), 1093-1114, 2021
442021
A multistage in silico study of natural potential inhibitors targeting SARS-CoV-2 main protease
EB Elkaeed, IH Eissa, H Elkady, A Abdelalim, AM Alqaisi, AA Alsfouk, ...
International Journal of Molecular Sciences 23 (15), 8407, 2022
402022
Design, synthesis, in vitro biological assessment and molecular modeling insights for novel 3-(naphthalen-1-yl)-4, 5-dihydropyrazoles as anticancer agents with potential EGFR …
WM Eldehna, MA El Hassab, ZM Elsayed, T Al-Warhi, H Elkady, ...
Scientific reports 12 (1), 12821, 2022
382022
The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches
EB Elkaeed, RG Yousef, H Elkady, IMM Gobaara, AA Alsfouk, DZ Husein, ...
Processes 10 (7), 1391, 2022
382022
Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: Design, synthesis, and in silico study
MM Alanazi, H Elkady, NA Alsaif, AJ Obaidullah, WA Alanazi, ...
Journal of Molecular Structure 1253, 132220, 2022
382022
Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 …
A Belal, NM Abdel Gawad, ABM Mehany, MAS Abourehab, H Elkady, ...
Journal of enzyme inhibition and medicinal chemistry 37 (1), 1884-1902, 2022
352022
Multi-phase in silico discovery of potential SARS-CoV-2 RNA-dependent RNA polymerase inhibitors among 3009 clinical and FDA-approved related drugs
EB Elkaeed, H Elkady, A Belal, BA Alsfouk, TH Ibrahim, M Abdelmoaty, ...
Processes 10 (3), 530, 2022
342022
(E)-N-(3-(1-(2-(4-(2,2,2-Trifluoroacetamido)benzoyl)hydrazono)ethyl)phenyl)nicotinamide: A Novel Pyridine Derivative for Inhibiting Vascular Endothelial Growth …
RG Yousef, H Elkady, EB Elkaeed, IMM Gobaara, HA Al-Ghulikah, ...
Molecules 27 (22), 7719, 2022
332022
The system can't perform the operation now. Try again later.
Articles 1–20